Research graph
References from Optimizing antibody-dependent cellular phagocytosis for cancer immunotherapy: mechanisms, constraints, and therapeutic strategies. Local targets link to admitted publications; unresolved targets remain external evidence.
Cellular cytotoxicity of next-generation CD20 monoclonal antibodies, cancer
2018 · External reference
Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies
10.1182/blood-2014-07-588376 · 2015 · External reference
Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis
10.1038/s41586-021-03879-4 · 2021 · External reference
The anti-B7-H4 checkpoint synergizes trastuzumab treatment to promote phagocytosis and eradicate breast cancer
10.1016/j.neo.2020.08.007 · 2020 · External reference
Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcγ receptors on macrophages
10.4049/jimmunol.1402891 · 2015 · External reference
CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis
10.1172/jci.insight.131882 · 2019 · External reference
Fcγ receptors and immunomodulatory antibodies in cancer
10.1038/s41568-023-00637-8 · 2023 · External reference
Antibody-mediated phagocytosis in cancer immunotherapy
10.1111/imr.13265 · 2023 · External reference
Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response
10.1073/pnas.1305569110 · 2013 · External reference
Facts and hopes in harnessing macrophage-mediated antibody-dependent cellular phagocytosis for cancer immunotherapy
10.1158/1078-0432.ccr-25-0434 · 2026 · External reference
Macrophage hypophagia as a mechanism of innate immune exhaustion in mAb-induced cell clearance
10.1182/blood.2020005571 · 2020 · External reference
Immune checkpoint inhibition overcomes ADCP-induced immunosuppression by macrophages
10.1016/j.cell.2018.09.007 · 2018 · External reference
Targeting phagocytosis checkpoints for cancer immunotherapy
10.1038/s41568-025-00893-w · 2025 · External reference
Antibody-dependent cellular phagocytosis by macrophages is a novel mechanism of action of elotuzumab
10.1158/1535-7163.mct-17-0998 · 2018 · External reference
SIRPα-specific monoclonal antibody enables antibody-dependent phagocytosis of neuroblastoma cells
10.1007/s00262-021-02968-7 · 2021 · External reference
KLRG1 cell depletion as a novel therapeutic strategy in patients with mature T-cell lymphoma subtypes
10.1158/1078-0432.ccr-23-3504 · 2024 · External reference
T cell-dependent bispecific therapy enhances innate immune activation and antibody-mediated killing
10.1158/2326-6066.cir-23-0072 · 2024 · External reference
Method for measurement of antibody-dependent cellular phagocytosis
10.1007/978-1-0716-1450-1_19 · 2022 · External reference
Avidity in antibody effector functions and biotherapeutic drug design
10.1038/s41573-022-00501-8 · 2022 · External reference
Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)
10.1038/s41467-025-58266-8 · 2025 · External reference
Enhancing complement activation by therapeutic anti-tumor antibodies: mechanisms, strategies, and engineering approaches
2024 · External reference
Human tumor-associated macrophages and neutrophils regulate antitumor antibody efficacy through lethal and sublethal trogocytosis
10.1158/0008-5472.can-23-2135 · 2024 · External reference
Trogocytosis-mediated immune evasion in the tumor microenvironment
2025 · External reference
Drugging the efferocytosis process: concepts and opportunities
10.1038/s41573-022-00470-y · 2022 · External reference
CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentation
10.1038/s41467-025-59326-9 · 2025 · External reference
Efferocytosis: the art of cellular clearance and novel perspectives in disease therapy
10.1186/s12943-025-02484-7 · 2025 · External reference
Cancer therapy with antibodies
10.1038/s41568-024-00690-x · 2024 · External reference
Effect of posttranslational modifications and subclass on IgG activity: from immunity to immunotherapy
10.1038/s41590-023-01544-8 · 2023 · External reference
Neutrophils as immune effector cells in antibody therapy in cancer
10.1111/imr.13159 · 2022 · External reference
Improving the efficacy of anti-SSEA4 antibody in pancreatic cancer immunotherapy with glyco-optimization and immune checkpoint blockade
10.1073/pnas.2517415122 · 2025 · External reference
Natural killer cell homing and trafficking in tissues and tumors: from biology to application
10.1038/s41392-022-01058-z · 2022 · External reference
An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
10.1038/s41467-023-37029-3 · 2023 · External reference
HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy
10.1186/s13046-022-02294-5 · 2022 · External reference
The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy
10.1084/jem.20040119 · 2004 · External reference
Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy
10.1126/sciadv.abl9171 · 2022 · External reference
The fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a
10.1136/jitc-2019-000413 · 2020 · External reference
Osteosarcoma cell-derived migrasomes promote macrophage M2 polarization to aggravate osteosarcoma proliferation and metastasis
2025 · External reference
Spatial single-cell proteomics landscape decodes the tumor microenvironmental ecosystem of intrahepatic cholangiocarcinoma
10.1097/hep.0000000000001283 · 2025 · External reference
NPLOC4 inhibition remodels tumor microenvironment via M2-to-M1 macrophage reprogramming and boosts anti-PD-1 response in liver cancer
10.7150/ijbs.125201 · 2026 · External reference
Targeted agents and immunotherapies: optimizing outcomes in melanoma
10.1038/nrclinonc.2017.43 · 2017 · External reference
Macrophages as tools and targets in cancer therapy
10.1038/s41573-022-00520-5 · 2022 · External reference
Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment
10.1073/pnas.1720948115 · 2018 · External reference
Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity, Journal of immunology (Baltimore
1950 · External reference
Developmentally regulated IgG Fc receptors on cultured human monocytes
10.1084/jem.167.2.408 · 1988 · External reference
IL-4/IL-4R axis signaling drives resistance to immunotherapy by inducing the upregulation of Fcγ receptor IIB in M2 macrophages
10.1038/s41419-024-06875-4 · 2024 · External reference
Red pulp macrophages in the human spleen are a distinct cell population with a unique expression of Fc-γ receptors
10.1182/bloodadvances.2017015008 · 2018 · External reference
Role of Fcγ receptors in HER2-targeted breast cancer therapy
10.1136/jitc-2021-003171 · 2022 · External reference
Differential regulation of human monocytes and NK cells by antibody-opsonized tumors
10.1007/s00262-018-2179-z · 2018 · External reference
Targeting the high affinity receptor, FcγRI, in autoimmune disease, neuropathy, and cancer
10.1093/immadv/ltac011 · 2022 · External reference
FcγRI and FcγRIII on splenic macrophages mediate phagocytosis of anti-glycoprotein IIb/IIIa autoantibody-opsonized platelets in immune thrombocytopenia
10.3324/haematol.2020.248385 · 2021 · External reference
Macrophage N-glycan processing inhibits antibody-dependent cellular phagocytosis
10.1093/glycob/cwad078 · 2023 · External reference
Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses
10.1182/blood-2008-09-179754 · 2008 · External reference
Serum immunoglobulin and the threshold of Fc receptor-mediated immune activation
10.1016/j.bbagen.2023.130448 · 2023 · External reference
The weaker-binding Fc γ receptor IIIa F158 allotype retains sensitivity to N-glycan composition and exhibits a destabilized antibody-binding interface
10.1016/j.jbc.2022.102329 · 2022 · External reference
Fc gamma receptors: their evolution, genomic architecture, genetic variation, and impact on human disease
10.1111/imr.13401 · 2024 · External reference
Adenovirus-mediated overexpression of FcγRIIB attenuates pulmonary inflammation and fibrosis
10.1165/rcmb.2022-0056oc · 2023 · External reference
Fc gamma receptor IIb in tumor-associated macrophages and dendritic cells drives poor prognosis of recurrent glioblastoma through immune-associated signaling pathways
10.3389/fgene.2022.1046008 · 2023 · External reference
A critical role for Syk in signal transduction and phagocytosis mediated by Fcgamma receptors on macrophages
10.1084/jem.186.7.1027 · 1997 · External reference
Fcgamma receptor-mediated phagocytosis in macrophages lacking the Src family tyrosine kinases Hck, Fgr, and Lyn
10.1084/jem.191.4.669 · 2000 · External reference
Lipid rafts and membrane dynamics
10.1242/jcs.01681 · 2005 · External reference
Cyclophosphamide enhances cancer antibody immunotherapy in the resistant bone marrow niche by modulating macrophage FcγR expression
10.1158/2326-6066.cir-18-0835 · 2019 · External reference
MST4 kinase regulates immune thrombocytopenia by phosphorylating STAT1-mediated M1 polarization of macrophages
10.1038/s41423-023-01089-8 · 2023 · External reference
Syk inhibitor attenuates lupus in FcγRIIb-/- mice through the Inhibition of DNA extracellular traps from macrophages and neutrophils via p38MAPK-dependent pathway
10.1038/s41420-025-02342-x · 2025 · External reference
The effect of phosphatases SHP-1 and SHIP-1 on signaling by the ITIM- and ITAM-containing Fcgamma receptors FcgammaRIIB and FcgammaRIIA
10.1189/jlb.0902454 · 2003 · External reference
FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms
10.1016/j.celrep.2022.111099 · 2022 · External reference
Tight nanoscale clustering of Fcγ receptors using DNA origami promotes phagocytosis
10.7554/elife.68311 · 2021 · External reference
Antibody binding geometry and affinity control inhibitory hFcγRIIB receptor signaling
10.1016/j.immuni.2026.05.019 · 2026 · External reference
Promoting macrophage phagocytosis of cancer cells for effective cancer immunotherapy
2024 · External reference
Omegasome-proximal PtdIns(4,5)P2 couples F-actin mediated mitoaggregate disassembly with autophagosome formation during mitophagy
10.1038/s41467-019-08924-5 · 2019 · External reference
Antibody-dependent cellular phagocytosis in antiviral immune responses
10.3389/fimmu.2019.00332 · 2019 · External reference
Glucose starvation increases V-ATPase assembly and activity in mammalian cells through AMP kinase and phosphatidylinositide 3-kinase/Akt signaling
10.1074/jbc.ra117.001327 · 2018 · External reference
Lysosomal quality control review
10.1080/15548627.2025.2469206 · 2025 · External reference
Modulation of Rab5 and Rab7 recruitment to phagosomes by phosphatidylinositol 3-kinase
10.1128/mcb.23.7.2501-2514.2003 · 2003 · External reference
Inhibitory receptor FcγRIIb mediates the effects of IgG on a phagosome acidification and a sequential dephosphorylation system comprising SHIPs and Inpp4a
10.1177/1753425917701553 · 2017 · External reference
10.1182/blood-2007-02-073874
10.1182/blood-2007-02-073874 · 2007 · External reference
Microtubules regulate PI-3K activity and recruitment to the phagocytic cup during Fcgamma receptor-mediated phagocytosis in nonelicited macrophages
10.1189/jlb.0706469 · 2007 · External reference
The myotubularin MTMR4 regulates phagosomal phosphatidylinositol 3-phosphate turnover and phagocytosis
10.1074/jbc.ra119.009133 · 2019 · External reference
Regulation of phospholipase D by Arf6 during FcγR-mediated phagocytosis
10.4049/jimmunol.1801019 · 2019 · External reference
A phosphatidylinositol-3-kinase-dependent signal transition regulates ARF1 and ARF6 during Fcgamma receptor-mediated phagocytosis
10.1371/journal.pbio.0040162 · 2006 · External reference
Transient recruitment of M-Ras GTPase to phagocytic cups in RAW264 macrophages during FcγR-mediated phagocytosis
10.1093/jmicro/dfx131 · 2018 · External reference
AP-1 and ARF1 control endosomal dynamics at sites of FcR mediated phagocytosis
10.1091/mbc.e07-04-0392 · 2007 · External reference
Semaphorin 3D promotes pancreatic ductal adenocarcinoma progression and metastasis through macrophage reprogramming
10.1126/sciadv.adp0684 · 2024 · External reference
TAMs-specific ARF1 inhibition reprograms glioma microenvironment and enhances the therapeutic effect of oncolytic adenovirus
10.1016/j.isci.2025.112696 · 2025 · External reference
Rab20 regulates phagosome maturation in RAW264 macrophages during Fc gamma receptor-mediated phagocytosis
10.1371/journal.pone.0035663 · 2012 · External reference
Rab31 and APPL2 enhance FcγR-mediated phagocytosis through PI3K/Akt signaling in macrophages
10.1091/mbc.e14-10-1457 · 2015 · External reference
Rab35 regulates phagosome formation through recruitment of ACAP2 in macrophages during FcγR-mediated phagocytosis
10.1242/jcs.083881 · 2011 · External reference
RAB-35 and ARF-6 GTPases mediate engulfment and clearance following linker cell-type death
10.1016/j.devcel.2018.08.015 · 2018 · External reference
Rho is required for the initiation of calcium signaling and phagocytosis by Fcgamma receptors in macrophages
10.1084/jem.186.6.955 · 1997 · External reference
Regulatory and signaling properties of the Vav family
10.1128/mcb.20.5.1461-1477.2000 · 2000 · External reference
A Cdc42 activation cycle coordinated by PI 3-kinase during Fc receptor-mediated phagocytosis
10.1091/mbc.e08-05-0494 · 2009 · External reference
Dissociation of recruitment and activation of the small G-protein Rac during Fcgamma receptor-mediated phagocytosis
10.1074/jbc.m513731200 · 2006 · External reference
Requirements for Vav guanine nucleotide exchange factors and Rho GTPases in FcgammaR- and complement-mediated phagocytosis
10.1016/j.immuni.2006.02.005 · 2006 · External reference
Localization of Rac2 via the C terminus and aspartic acid 150 specifies superoxide generation, actin polarity and chemotaxis in neutrophils
10.1038/ni1081 · 2004 · External reference
Hyperactive Rac stimulates cannibalism of living target cells and enhances CAR-M-mediated cancer cell killing
10.1073/pnas.2310221120 · 2023 · External reference
RhoG is required for both FcγR- and CR3-mediated phagocytosis
10.1242/jcs.084269 · 2011 · External reference
Involvement of Tiam1, RhoG and ELMO2/ILK in Rac1-mediated phagocytosis in human trabecular meshwork cells
10.1016/j.yexcr.2016.08.009 · 2016 · External reference
Identification of two distinct mechanisms of phagocytosis controlled by different Rho GTPases
10.1126/science.282.5394.1717 · 1998 · External reference
Rho-kinase and myosin-II control phagocytic cup formation during CR, but not FcgammaR, phagocytosis
10.1016/s0960-9822(02)01069-2 · 2002 · External reference
RhoC regulates the actin remodeling required for phagosome formation during FcγR-mediated phagocytosis
10.1242/jcs.202739 · 2017 · External reference
Vav regulates activation of Rac but not Cdc42 during FcgammaR-mediated phagocytosis
10.1091/mbc.02-01-0002 · 2002 · External reference
Calcium signaling commands phagosome maturation process
10.1080/08830185.2019.1592169 · 2019 · External reference
NADPH oxidase controls phagosomal pH and antigen cross-presentation in human dendritic cells
10.1182/blood-2008-01-134791 · 2008 · External reference
Ligation of FcγR alters phagosomal processing of protein via augmentation of NADPH oxidase activity
10.1111/tra.12396 · 2016 · External reference
Differential requirement for classic and novel PKC isoforms in respiratory burst and phagocytosis in RAW 264.7 cells
10.4049/jimmunol.165.5.2809 · 2000 · External reference
The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology
10.1152/physrev.00044.2005 · 2007 · External reference
Autophagy proteins are not universally required for phagosome maturation
10.1080/15548627.2016.1191724 · 2016 · External reference
FcγR-driven release of IL-6 by macrophages requires NOX2-dependent production of reactive oxygen species
10.1074/jbc.m113.474106 · 2013 · External reference
The role of CD38 in Fcγ receptor (FcγR)-mediated phagocytosis in murine macrophages
10.1074/jbc.m111.329003 · 2012 · External reference
IRE1α promotes phagosomal calcium flux to enhance macrophage fungicidal activity
10.1016/j.celrep.2025.115694 · 2025 · External reference
Fc-mediated immune stimulating, pro-inflammatory and antitumor effects of anti-HER2 IgE against HER2-expressing and trastuzumab-resistant tumors
10.1136/jitc-2024-010945 · 2025 · External reference
SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the “don't eat me” signal and activating the “eat me” signal
10.1186/s13045-022-01385-2 · 2022 · External reference
PSD3 links autophagic flux to MHC-I-associated immune modulation in esophageal squamous cell carcinoma
10.1007/s10495-026-02345-8 · 2026 · External reference
Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy
10.1016/j.drup.2024.101068 · 2024 · External reference
Macrophages are activated toward phagocytic lymphoma cell clearance by pentose phosphate pathway inhibition
2024 · External reference
IgA-dependent cell phagocytosis of HIV-infected cells elicits cross-presentation to CD8+T cells and immune memory in effector monocytes
10.1016/j.mucimm.2025.09.004 · 2025 · External reference
Resolving the difference between left-sided and right-sided colorectal cancer by single-cell sequencing
10.1172/jci.insight.152616 · 2022 · External reference
Cancer cell phagocytosis induces an anti-inflammatory gene regulatory program in macrophages
2025 · External reference
Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab
10.1158/1078-0432.ccr-11-0239 · 2011 · External reference
Therapeutic targeting of the hypoxic tumour microenvironment
10.1038/s41571-021-00539-4 · 2021 · External reference
Myeloid-derived suppressor cells in cancer and cancer therapy
10.1038/s41571-023-00846-y · 2024 · External reference
Single-cell spatial pharmacobiology identifies conserved stromal barriers to therapeutic antibody delivery in human solid tumors
10.1038/s41587-026-03152-x · 2026 · External reference
Molecular Force Imaging reveals that Integrin-Dependent Mechanical Checkpoint Regulates Fcγ-Receptor-Mediated Phagocytosis in Macrophages
10.1021/acs.nanolett.3c00957 · 2023 · External reference
The immunomechanical checkpoint PYK2 governs monocyte-to-macrophage differentiation in pancreatic cancer
10.1158/2159-8290.cd-24-1712 · 2025 · External reference
The burgeoning significance of liquid-liquid phase separation in the pathogenesis and therapeutics of cancers
10.7150/ijbs.92988 · 2024 · External reference
Disorders of cancer metabolism: the therapeutic potential of cannabinoids
2022 · External reference
Tumor cell-targeting and tumor microenvironment-responsive nanoplatforms for the multimodal imaging-guided photodynamic/photothermal/chemodynamic treatment of cervical cancer
10.2147/ijn.s466042 · 2024 · External reference
TPL-2 kinase induces phagosome acidification to promote macrophage killing of bacteria
10.15252/embj.2020106188 · 2021 · External reference
Macrophages are metabolically heterogeneous within the tumor microenvironment
10.1016/j.celrep.2021.110171 · 2021 · External reference
Glutamine alleviates immunosuppression in polymicrobial sepsis by augmenting bacterial phagocytosis through sustaining the GFAT-DRP1 dependent mitochondrial calcium dynamics
10.1042/cs20256651 · 2025 · External reference
Tofacitinib suppresses IL-10/IL-10R signaling and modulates host defense responses in human macrophages
2021 · External reference
Overcoming TGFβ-mediated immune evasion in cancer
10.1038/s41568-021-00413-6 · 2021 · External reference
Immunotherapy and the ovarian cancer microenvironment: exploring potential strategies for enhanced treatment efficacy
10.1111/imm.13793 · 2024 · External reference
Role of CD47 as a marker of self on red blood cells
10.1126/science.288.5473.2051 · 2000 · External reference
Phagocytosis checkpoints as new targets for cancer immunotherapy
10.1038/s41568-019-0183-z · 2019 · External reference
Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives
2024 · External reference
Targeting tumor-associated macrophages to synergize tumor immunotherapy
10.1038/s41392-021-00484-9 · 2021 · External reference
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study
10.1182/blood.2024027408 · 2025 · External reference
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy
10.1182/blood.2024027506 · 2025 · External reference
Cooperative phagocytosis of solid tumours by macrophages triggers durable anti-tumour responses
10.1038/s41551-023-01031-3 · 2023 · External reference
Therapeutic antibodies for the prevention and treatment of cancer
10.1186/s12929-024-00996-w · 2024 · External reference
HCB101: a novel potent ligand-trap Fc-fusion protein targeting the CD47-SIRPα pathway with high safety and preclinical efficacy for hematological and solid tumors
10.1186/s13045-025-01742-x · 2025 · External reference
Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies
10.1096/fj.201701544r · 2018 · External reference
A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC
10.1016/j.ymthe.2021.01.006 · 2021 · External reference
Harnessing the innate immune system: a novel bispecific antibody targeting CD47 and CD24 for selective tumor clearance
10.1136/jitc-2025-013283 · 2025 · External reference
Guselkumab binding to CD64+ IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling
10.3389/fimmu.2025.1532852 · 2025 · External reference
An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts
10.1182/blood-2017-01-764316 · 2017 · External reference
Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells
10.1158/1535-7163.mct-08-0201 · 2008 · External reference
Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity
10.1074/jbc.m202069200 · 2002 · External reference
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia
10.1136/jitc-2020-002026 · 2021 · External reference
Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia
10.1182/blood.2019001750 · 2019 · External reference
An Fc-engineered glycomodified antibody supports proinflammatory activation of immune effector cells and restricts progression of breast cancer
10.1158/0008-5472.can-24-3174 · 2025 · External reference
Cell-based glycoengineering for production of homogeneous and specific glycoform-enriched antibodies with improved effector functions
2025 · External reference
The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity
10.1074/jbc.m210665200 · 2002 · External reference
Cross-species analysis of FcγRIIa/b (CD32a/b) polymorphisms at position 131: structural and functional insights into the mechanism of IgG- mediated phagocytosis in human and macaque
10.3389/fimmu.2025.1726068 · 2025 · External reference
Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors
10.1080/19420862.2021.1950264 · 2021 · External reference
Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy
10.3389/fimmu.2022.1039969 · 2023 · External reference
Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice
10.1136/jitc-2023-008295 · 2024 · External reference
Enhancing antibody-dependent cellular phagocytosis by Re-education of tumor-associated macrophages with resiquimod-encapsulated liposomes
2020 · External reference
Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis
10.1080/2162402x.2020.1859263 · 2021 · External reference
An engineered α1β1 integrin-mediated FcγRI signaling component to control enhanced CAR macrophage activation and phagocytosis
10.1016/j.jconrel.2024.11.064 · 2024 · External reference
Lifespan-regulated CAR-macrophages from myeloid progenitors for enhanced colorectal cancer therapy
2025 · External reference
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
10.1073/pnas.1520032112 · 2015 · External reference
Obinutuzumab activates FcγRI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL)
10.1080/2162402x.2018.1428158 · 2018 · External reference
Development of anti-CD32b antibodies with enhanced Fc function for the treatment of B and plasma Cell malignancies
10.1158/1535-7163.mct-19-0003 · 2020 · External reference
FcγRIIB is an immune checkpoint limiting the activity of treg-targeting antibodies in the tumor microenvironment
10.1158/2326-6066.cir-23-0389 · 2024 · External reference
The benefits and safety of monoclonal antibodies: implications for cancer immunotherapy
10.2147/jir.s499403 · 2025 · External reference
Reviving dormant immunity: millimeter waves reprogram the immunosuppressive microenvironment to potentiate immunotherapy without obvious side effects
10.34133/cbsystems.0468 · 2025 · External reference
Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα
10.1080/19420862.2019.1624123 · 2019 · External reference
Membrane nanoclusters of FcγRI segregate from inhibitory SIRPα upon activation of human macrophages
10.1083/jcb.201608094 · 2017 · External reference
Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages
10.3389/fimmu.2022.929339 · 2022 · External reference
Silencing of SIRPα enhances the antitumor efficacy of CAR-M in solid tumors
10.1038/s41423-024-01220-3 · 2024 · External reference
A novel, fully human anti-fucosyl-GM1 antibody demonstrates potent in vitro and in vivo antitumor activity in preclinical models of small cell lung cancer
10.1158/1078-0432.ccr-18-0018 · 2018 · External reference
Murlentamab, a low fucosylated anti-Müllerian hormone type II receptor (AMHRII) antibody, exhibits anti-tumor activity through tumor-associated macrophage reprogrammation and T cell activation
10.3390/cancers13081845 · 2021 · External reference
Disrupting USP14-mediated PARP1 dynamics reinstates MIC-A/B-driven antigen-independent CD8+ T cell killing in glioma
2026 · External reference
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
10.1182/blood-2009-06-225979 · 2010 · External reference
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
10.1080/19420862.2015.1007813 · 2015 · External reference
Daratumumab or active monitoring for high-risk smoldering multiple myeloma
10.1056/nejmoa2409029 · 2024 · External reference
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
10.1182/blood-2013-10-535088 · 2014 · External reference
CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody
10.1182/blood-2009-06-229039 · 2009 · External reference
IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma
10.1158/0008-5472.can-14-1456 · 2014 · External reference
ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade
10.4161/mabs.27398 · 2013 · External reference
Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia
10.1056/nejmoa1713976 · 2018 · External reference
Trastuzumab–mechanism of action and use in clinical practice
10.1056/nejmra043186 · 2007 · External reference
PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
10.1038/s41467-019-10127-x · 2019 · External reference
The PRL3-zumab paradigm: a multicenter, single-dose-level phase 2 basket clinical trial design of an unconventional cancer immunotherapy
2025 · External reference
Antitumor immune mechanisms of the anti-complement factor H antibody GT103
10.1158/1535-7163.mct-22-0723 · 2023 · External reference
Unlocking the full potential of memory T cells in adoptive T cell therapy for hematologic malignancies
2024 · External reference
Embracing life while confronting mortality: Therapeutic mechanisms of travel for cancer patients
10.1016/j.tourman.2025.105362 · 2026 · External reference
Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma
10.1158/1078-0432.ccr-09-2697 · 2010 · External reference
Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties
10.1186/bcr3069 · 2011 · External reference
Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia
10.1158/0008-5472.can-08-2268 · 2008 · External reference
Characterization of zolbetuximab in pancreatic cancer models
2018 · External reference
Dinutuximab: first global approval
10.1007/s40265-015-0399-5 · 2015 · External reference
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets
10.1038/74704 · 2000 · External reference
Evaluation of preclinical activity of isatuximab in patients with acute lymphoblastic leukemia
10.1158/1535-7163.mct-21-0058 · 2021 · External reference
EGFR Exon 20 insertions in NSCLC: from biology to amivantamab, optimal treatment strategy and emerging therapeutics
10.1080/14796694.2025.2550927 · 2025 · External reference
A pharmacological and clinical profile of Naxitamab for the treatment of high-risk neuroblastoma
10.1080/17512433.2025.2577716 · 2025 · External reference
